

**SPEVIGO  
(spesolimab-sbzo)**

**Pre - PA Allowance**

None

---

**Prior-Approval Requirements**

**Age** 12 years of age or older

**Diagnosis**

Patient must have the following:

1. Generalized pustular psoriasis (GPP)
  - a. GPP flares are of moderate-to-severe intensity (e.g., at least 5% of body surface area covered with erythema and the presence of pustules)

**AND ALL** of the following:

1. Patient has had an inadequate treatment response, intolerance, or contraindication to **ONE** of the following:
  - a. Methotrexate
  - b. Cyclosporine
  - c. Oral retinoid
2. Patient weight  $\geq 40\text{kg}$
3. Prescriber agrees to monitor for hypersensitivity reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS)
4. Result for latent TB infection is negative **OR** result was positive for latent TB and patient completed treatment (or is receiving treatment) for latent TB
5. Absence of active infection (including tuberculosis)
6. **NOT** used in combination with any other biologic DMARD or targeted synthetic DMARD (see Appendix 1)
7. **NOT** given concurrently with live vaccines

**Prior - Approval Limits**

**Quantity** 4 IV vials + 26 SC syringes

**Duration** 12 months

---

**Prior – Approval *Renewal* Requirements**

**Age** 12 years of age or older

**SPEVIGO  
(spesolimab-sbzo)**

**Diagnosis**

Patient must have the following:

1. Generalized pustular psoriasis (GPP)
  - a. Improvement or stabilization of patient's condition (e.g., reduction in the frequency or severity of flares)

**AND ALL** of the following:

1. Patient weight  $\geq$  40kg
2. Prescriber agrees to monitor for hypersensitivity reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS)
3. Absence of active infection (including tuberculosis)
4. **NOT** used in combination with any other biologic DMARD or targeted synthetic DMARD (see Appendix 1)
5. **NOT** given concurrently with live vaccines

**Prior - Approval *Renewal* Limits**

Same as above

**SPEVIGO  
(spesolimab-sbzo)**

**Appendix 1 - List of DMARDs  
Biological disease-modifying antirheumatic drugs (DMARDs)**

<b>Generic Name</b>	<b>Brand Name</b>
abatacept	Orencia
adalimumab	Humira
anakinra	Kineret
bimekizumab-bkzx	Bimzelx
brodalumab	Siliq
certolizumab	Cimzia
etanercept	Enbrel
golimumab	Simponi/Simponi Aria
guselkumab	Tremfya
infliximab	Remicade
ixekizumab	Taltz
risankizumab-rzaa	Skyrizi
rituximab	Rituxan
sarilumab	Kevzara
secukinumab	Cosentyx
spesolimab-sbzo	Spevigo
tildrakizumab-asmn	Ilumya
tocilizumab	Actemra
ustekinumab	Stelara
vedolizumab	Entyvio

**Targeted synthetic disease-modifying antirheumatic drugs  
(DMARDs)**

<b>Generic Name</b>	<b>Brand Name</b>
apremilast	Otezla
baricitinib	Olumiant
deucravacitinib	Sotyktu
tofacitinib	Xeljanz/XR
upadactinib	Rinvoq